Is PCSA or PHAR more undervalued in 2026?

CirclFi compares Processa Pharmaceuticals, Inc. (PCSA) and Pharming Group N.V. (PHAR) using 13 institutional-grade valuation models. PCSA has a Quality of Company score of 3.7/10 while PHAR scores 2.1/10.

Which is a better buy — PCSA or PHAR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PCSA and PHAR valuations compare?

PCSA at $2.64 and PHAR at $13.66 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PCSA vs PHAR Valuation Comparison 2026 — Intrinsic Value Analysis

PCSA

Biotechnology

Processa Pharmaceuticals, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$2.64

Last close

Models

7/13

Active

PHAR

Biotechnology

Pharming Group N.V.

Quality

2.1

out of 10

Value Trap

—

Price

$13.66

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	PCSA Fair Value	PCSA Upside	PHAR Fair Value	PHAR Upside
Bayesian DCF	Intrinsic	$1.04	-60.5%	$2.75	-79.9%
Earnings Power Value	Intrinsic	—	—	$4.28	-73.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.20	-93.4%	$8.30	-39.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PCSA vs PHAR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PCSA vs PHAR — Which Stock Is More Undervalued?

PCSA scores higher with a 3.7/10 quality rating vs PHAR's 2.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Processa Pharmaceuticals, Inc. (PCSA) and Pharming Group N.V. (PHAR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PCSA currently trades at $2.64 with a QOC of 3.7/10, while PHAR trades at $13.66 with a QOC of 2.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).